These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 31604531)

  • 1. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
    ElTanbouly MA; Croteau W; Noelle RJ; Lines JL
    Semin Immunol; 2019 Apr; 42():101308. PubMed ID: 31604531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VISTA: Coming of age as a multi-lineage immune checkpoint.
    ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
    Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VISTA: A Target to Manage the Innate Cytokine Storm.
    ElTanbouly MA; Zhao Y; Schaafsma E; Burns CM; Mabaera R; Cheng C; Noelle RJ
    Front Immunol; 2020; 11():595950. PubMed ID: 33643285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VISTA: A Novel Checkpoint for Cancer Immunotherapy.
    Gao Y; He Y; Tang Y; Chen ZS; Qu M
    Drug Discov Today; 2024 Jul; 29(7):104045. PubMed ID: 38797321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
    Yuan L; Tatineni J; Mahoney KM; Freeman GJ
    Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.
    Huang X; Zhang X; Li E; Zhang G; Wang X; Tang T; Bai X; Liang T
    J Hematol Oncol; 2020 Jun; 13(1):83. PubMed ID: 32600443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
    Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
    Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoregulatory functions of VISTA.
    Nowak EC; Lines JL; Varn FS; Deng J; Sarde A; Mabaera R; Kuta A; Le Mercier I; Cheng C; Noelle RJ
    Immunol Rev; 2017 Mar; 276(1):66-79. PubMed ID: 28258694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
    Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
    J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance.
    Schaafsma E; Croteau W; ElTanbouly M; Nowak EC; Smits NC; Deng J; Sarde A; Webber CA; Rabadi D; Cheng C; Noelle R; Lines JL
    Cancer Immunol Res; 2023 Jan; 11(1):38-55. PubMed ID: 36260656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
    Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
    Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VISTA: A promising target for overcoming immune evasion in gynecologic cancers.
    Liu S; Ji F; Ding Y; Ding B; Feng S; Brennick C; Lin H; Zhang T; Shen Y
    Int Immunopharmacol; 2024 Sep; 138():112655. PubMed ID: 38986302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
    Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():676181. PubMed ID: 34093577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
    Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
    Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: a Bibliometric study.
    Ait Boujmia OK
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jun; 394(6):1057-1065. PubMed ID: 33616679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VISTA expression and patient selection for immune-based anticancer therapy.
    Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
    Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA.
    Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J
    BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
    Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
    Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.
    Xu W; Hiếu T; Malarkannan S; Wang L
    Cell Mol Immunol; 2018 May; 15(5):438-446. PubMed ID: 29375120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.